利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.027 秒)

    Diagnosis and prognosis of colorectal cancer
    6.
    发明授权
    Diagnosis and prognosis of colorectal cancer 有权
    结直肠癌的诊断和预后

    公开(公告)号：US09095549B2

    公开(公告)日：2015-08-04

    申请号：US12097703

    申请日：2006-12-15

    申请人： Richard Joubert ,  Petra Prefot ,  Gitte Boehm ,  Juergen Arnhold ,  Claudia Hoehle ,  Erhard Neukum ,  Juergen Schaefer

    发明人： Richard Joubert ,  Petra Prefot ,  Gitte Boehm ,  Juergen Arnhold ,  Claudia Hoehle ,  Erhard Neukum ,  Juergen Schaefer

    IPC分类号： G01N33/53 ,  A61K38/17 ,  G01N33/574

    CPC分类号： A61K38/17 ,  G01N33/57419

    摘要： The invention relates to a method of diagnosis of colorectal cancer in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a control, normal human sample, the protein being: transforming growth factor-beta induced protein IG-H3 (SwissProt Acc. No. Q15582); suppressor of G2 allele of SKP1 homolog (isoform 2) (SwissProt Acc. No. Q9Y2Z0-2); hypothetical protein (part of URG4) (SwissProt Acc. No. Q9NWR7); calponin-2 (SwissProt Acc. No. Q99439); heat shock protein HSP90-beta (SwissProt Acc. No. P08238); phosphoglycerate mutase 1 (SwissProt Acc. No. P18669); serpin C1 protein (SwissProt Acc. No. P01008); or haptoglobin precursor (SwissProt Acc. No. P00738); or a decreased concentration of a protein in the diagnostic sample, compared with a control, normal human sample, the protein being serotransferrin (SwissProt Acc. No. P02787); 26S proteasome subunit p40.5 (Swiss Prot Acc. No. Q9UNM7); aldo-keto reductase family 1 member B10 (SwissProt Acc. No. O60218); fructosamine-3-kinase (SwissProt Acc. No. Q9H479); peripherin (SwissProt Acc. No. P41219); alpha-2-macroglobulin (SwissProt Acc. No. P01023); serpin C1 protein (SwissProt Acc. No. P01008); or apolipoprotein A IV (SwissProt Acc. No. P06727). The same proteins can be used for prognosis by detecting changes in their concentration in the course of treatment for colorectal cancer.

    摘要翻译： 本发明涉及一种从人体受试者获得的有效身体组织的诊断样本中诊断结肠直肠癌的方法，其包括检测诊断样品中蛋白质浓度的增加，与正常人类样品相比， 蛋白质是：转化生长因子-β诱导的蛋白质IG-H3（SwissProt Acc。No.Q15582）; SKP1同源物（同种型2）（SwissProt Acc。No.Q9Y2Z0-2）的G2等位基因的抑制子; 假定蛋白（URG4的一部分）（SwissProt Acc。No.Q9NWR7）; calponin-2（SwissProt Acc。No.Q99439）; 热休克蛋白HSP90-β（SwissProt Acc。No.P08238）; 磷酸甘油酸变位酶1（SwissProt Acc。编号P18669）; 丝氨酸蛋白酶C1蛋白（SwissProt Acc。编号P01008）; 或触珠蛋白前体（SwissProt Acc.P00738）; 或者与正常人样品相比，该蛋白质是血清转铁蛋白（SwissProt Acc.No.P02787）; 26S蛋白酶体亚基p40.5（Swiss Prot Acc。No.Q9UNM7）; 醛醇还原酶家族1成员B10（SwissProt Acc.No.O60218）; 果糖胺-3-激酶（SwissProt Acc。No.Q9H479）; 外周蛋白（SwissProt Acc。No. P41219）; α-2-巨球蛋白（SwissProt Acc.Po1023）; 丝氨酸蛋白酶C1蛋白（SwissProt Acc。编号P01008）; 或载脂蛋白A IV（SwissProt Acc.Po6727）。 通过检测结肠直肠癌治疗过程中其浓度的变化可以将相同的蛋白质用于预后。

    DIAGNOSIS AND PROGNOSIS OF COLORECTAL CANCER
    8.
    发明申请
    DIAGNOSIS AND PROGNOSIS OF COLORECTAL CANCER 有权
    彩色癌症的诊断和预防

    公开(公告)号：US20090226905A1

    公开(公告)日：2009-09-10

    申请号：US12097703

    申请日：2006-12-15

    申请人： Richard Joubert ,  Petra Prefot ,  Gitte Boehm ,  Juergen Arnhold ,  Claudia Hoehle ,  Erhard Neukum ,  Juergen Schaefer

    发明人： Richard Joubert ,  Petra Prefot ,  Gitte Boehm ,  Juergen Arnhold ,  Claudia Hoehle ,  Erhard Neukum ,  Juergen Schaefer

    IPC分类号： G01N33/53 ,  C12Q1/68

    CPC分类号： A61K38/17 ,  G01N33/57419

    摘要： The invention relates to a method of diagnosis of colorectal cancer in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a control, normal human sample, the protein being: transforming growth factor-beta induced protein IG-H3 (SwissProt Acc. No. Q15582); suppressor of G2 allele of SKP1 homolog (isoform 2) (SwissProt Acc. No. Q9Y2Z0-2); hypothetical protein (part of URG4) (SwissProt Acc. No. Q9NWR7); calponin-2 (SwissProt Acc. No. Q99439); heat shock protein HSP90-beta (SwissProt Acc. No. P08238); phosphoglycerate mutase 1 (SwissProt Acc. No. P18669); serpin Cl protein (SwissProt Acc. No. P01008); or haptoglobin precursor (SwissProt Acc. No. P00738); or a decreased concentration of a protein in the diagnostic sample, compared with a control, normal human sample, the protein being serotransferrin (SwissProt Acc. No. P02787); 26S proteasome subunit p40.5 (Swiss Prot Acc. No. Q9UNM7); aldo-keto reductase family 1 member B10 (SwissProt Acc. No. O60218); fructosamine-3-kinase (SwissProt Acc. No. Q9H479); peripherin (SwissProt Acc. No. P41219); alpha-2-macroglobulin (SwissProt Acc. No. P01023); serpin C1 protein (SwissProt Acc. No. P01008); or apolipoprotein A IV (SwissProt Acc. No. P06727). The same proteins can be used for prognosis by detecting changes in their concentration in the course of treatment for colorectal cancer.

    摘要翻译： 本发明涉及一种从人体受试者获得的有效身体组织的诊断样本中诊断结肠直肠癌的方法，其包括检测诊断样品中蛋白质浓度的增加，与正常人类样品相比， 蛋白质是：转化生长因子-β诱导的蛋白质IG-H3（SwissProt Acc。No.Q15582）; SKP1同源物（同种型2）（SwissProt Acc。No.Q9Y2Z0-2）的G2等位基因的抑制子; 假定蛋白（URG4的一部分）（SwissProt Acc。No.Q9NWR7）; calponin-2（SwissProt Acc。No.Q99439）; 热休克蛋白HSP90-β（SwissProt Acc。No.P08238）; 磷酸甘油酸变位酶1（SwissProt Acc。编号P18669）; 丝氨酸蛋白酶C1蛋白（SwissProt Acc。编号P01008）; 或触珠蛋白前体（SwissProt Acc.P00738）; 或者与正常人样品相比，该蛋白质是血清转铁蛋白（SwissProt Acc.No.P02787）; 26S蛋白酶体亚基p40.5（Swiss Prot Acc。No.Q9UNM7）; 醛醇还原酶家族1成员B10（SwissProt Acc.No.O60218）; 果糖胺-3-激酶（SwissProt Acc。No.Q9H479）; 外周蛋白（SwissProt Acc。No. P41219）; α-2-巨球蛋白（SwissProt Acc.Po1023）; 丝氨酸蛋白酶C1蛋白（SwissProt Acc。编号P01008）; 或载脂蛋白A IV（SwissProt Acc.Po6727）。 通过检测结肠直肠癌治疗过程中其浓度的变化可以将相同的蛋白质用于预后。